Health · Pharma & Biotech · 9 hrs ago
FDA approves dostarlimab for some patients with operable rectal cancer
The FDA granted accelerated approval to dostarlimab on Monday.
The drug, also called Jemperli, is a PD-1 inhibitor for selected patients with operable stage II or III rectal cancer.
The approval is intended to help some of these patients potentially avoid surgery.
It applies to a selected group, not to all people with rectal cancer.
The source does not say that surgery can be avoided in every case.
It gives no further details on treatment or what happens next.
The FDA granted accelerated approval to dostarlimab, also called Jemperli, for some patients with operable rectal cancer.
The treatment is intended to help selected patients potentially avoid surgery.
The approval covers patients with stage II or stage III disease.
- Who
- The FDA approved dostarlimab for selected patients with operable rectal cancer.
- What
- It granted accelerated approval for the drug, also called Jemperli.
- When
- Monday, October 19, 2026.
- Where
- Not stated.
- Why
- The treatment may help selected patients avoid surgery.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Dostarlimab, also called Jemperli
- Approval
- Accelerated FDA approval
- Eligible disease stages
- Stage II/III
- Target patients
- Some patients with operable rectal cancer